Bernardino Alcazar-Navarrete
Overview
Explore the profile of Bernardino Alcazar-Navarrete including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romero-Palacios P, Alcazar-Navarrete B
ERJ Open Res
. 2025 Mar;
11(2).
PMID: 40071271
https://bit.ly/3Z9qNOb.
2.
Hammadi A, Hoyas-Sanchez C, Romero-Linares A, Alvarez-Muro L, Menendez-Lobo A, Romeral-Navarro D, et al.
Arch Bronconeumol
. 2025 Mar;
PMID: 40050216
Introduction: COPD is a major public health concern, often complicated by cardiovascular comorbidities. Single inhaler triple therapy (SITT) has been proposed as a superior treatment option compared to single inhaler...
3.
Garcia-Diaz A, Moyano-Rodriguez M, Garrido-Navas M, de Miguel-Perez D, Exposito-Hernandez J, Alcazar-Navarrete B, et al.
Arch Bronconeumol
. 2024 Oct;
61(3):156-165.
PMID: 39414465
Introduction: Non-small cell lung cancer (NSCLC) is the most common type of lung neoplasm. Despite surgical resection, it has a high relapse rate, accounting for 30-55% of all cases. Next-generation...
4.
Sanchez-Garcia M, Alcazar-Navarrete B, Cortinas-Saenz M, Cordero Tous N, Galvez Mateos R
Healthcare (Basel)
. 2024 Sep;
12(18).
PMID: 39337211
Intrathecal drug delivery (IDD) is part of the fourth analgesic step. Evidence on the quality of life of patients with refractory chronic non-cancer pain (CNCP) using these devices and their...
5.
Agusti A, Lopez-Campos J, Miravitlles M, Soler-Cataluna J, Marin J, Cosio B, et al.
Arch Bronconeumol
. 2024 May;
60(7):417-422.
PMID: 38729884
Introduction: Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control (CC), a composite...
6.
Romero Ortiz A, Jimenez-Rodriguez B, Lopez-Ramirez C, Lopez-Bauza A, Perez-Morales M, Delgado-Torralbo J, et al.
BMJ Open Respir Res
. 2024 Apr;
11(1).
PMID: 38663886
Background: Idiopathic pulmonary fibrosis (IPF) is a rare disorder associated with increased mortality and morbidity. There are currently two drugs approved for IPF but their safety and efficacy profile in...
7.
Almonacid-Sanchez C, Cosio B, Trisan-Alonso A, Callejas-Gonzalez F, Cisneros C, Martinez-Moragon E, et al.
Arch Bronconeumol
. 2023 Oct;
59(12):842-845.
PMID: 37865605
No abstract available.
8.
Ramirez-Rodriguez G, Menendez-Lobo A, Romero-Linares A, Bernabeu-Fernandez de Liencres M, Romero-Palacios P, Alcazar-Navarrete B
Med Clin (Barc)
. 2023 Oct;
162(1):9-14.
PMID: 37813726
Introduction: Mortality from COPD has decreased in Spain in recent years, but it is unknown whether this decline has been homogeneous among the different regions. Methods: From the Statistical Portal...
9.
de la Vina J, Ramirez-Rodriguez G, Alcazar-Navarrete B
Arch Bronconeumol
. 2022 Jul;
58(10):687-688.
PMID: 35879121
No abstract available.
10.
Alcazar-Navarrete B, Jamart L, Sanchez-Covisa J, Juarez M, Graefenhain R, Sicras-Mainar A
Chest
. 2022 Jul;
162(5):1017-1029.
PMID: 35787391
Background: COPD is a leading cause of death and disability. COPD therapy goals include reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) or multiple-inhaler triple therapy (MITT) is...